GlobeNewswire BiotechnologyDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 18:45:00·⟳ 抓取 18:45:44·⚡ 决策 10-20 18:46:24 +40s·6.8 天前
BioNTech宣布将于2026年11月3日公布三季报并召开电话会，仅为财报日程通知
这是一则例行财报日期/电话会安排公告，全文没有任何数字、指引、管线进展或超预期内容，预期差为零；在11月3日实际业绩披露前不存在基于本事件的方向性 edge，行情/KB/先例均不可能把一条纯日程通知变成交易机会，故早停并 AVOID。
📄 原文GlobeNewswire Biotechnology↗ 原文
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announ…
不做 BioNTech SE（BNTX.US）
例行财报日期通知，无业绩/指引/管线增量，预期差为零、无方向性 edge；不在11月3日实际数据披露前凭日程开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BioNTech 仅通知11月3日发财报，无任何业绩或指引增量；日程公告不产生可交易预期差，等待财报当日再判。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正波动来自11月3日Q3实际数据与公司更新，本通知无法预判方向，提前布局等于无信息赌博。
先例如何影响了这次决策
对本次决策的影响:未据此产生任何仓位；待11月3日实际财报发布时再做完整先例与预期差研究。
方向:不适用——纯财报日程通知，无事件性经济冲击，无需用历史先例校准方向或涨幅。
涨幅量级:无增量信息，不存在可定价幅度。
形态:不适用。
原文全文
展开原文 · 2,141 字
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE)
–
BioNTech SE
(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this
link
. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this
link
.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at
www.BioNTech.com
. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit
www.BioNTech.com
.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
–
BioNTech SE
(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this
link
. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this
link
.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at
www.BioNTech.com
. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit
www.BioNTech.com
.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
147b0e0e25· 2026-10-20 18:46 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前